HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Cohen, J. I. Articles by Seidel, K. E. Search for Related Content PubMed PubMed Citation Articles by Cohen, J. I. Articles by Seidel, K. E. Agricola Articles by Cohen, J. I. Articles by Seidel, K. E.

Absence of Varicella-zoster Virus (VZV) Glycoprotein V Does not Alter Growth of VZV in vitro or Sensitivity to Heparin

Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, U.S.A.

Varicella-zoster virus (VZV) encodes at least five glycoproteins, gpI to gpV. VZV gpV, M_r 100K to 110K, is the product of VZV open reading frame (ORF) 14. VZV gpV is homologous to herpes simplex virus gC and pseudorabies virus gIII. To determine whether gpV is required for viral replication, we inserted a stop codon after the fifteenth codon of the ORF14 gene in a cosmid containing the gene. Transfection of human melanoma cells with the cosmid containing the mutant ORF14 gene and three other cosmids resulted in the production of infectious VZV. Immunoprecipitation indicated that the mutant virus did not express gpV. VZV that did not express gpV grew at the same rate as parental virus and was inhibited by heparin to a similar extent. The pattern of inhibition by heparin of the gpV mutant was similar to that reported for a herpes simplex virus mutant that does not contain gC, but different from that described for a pseudorabies virus mutant devoid of gIII. These results indicate that VZV gpV is not required for viral replication in vitro.

Received 14 January 1994; accepted 14 June 1994.

This article has been cited by other articles:

				G. R. Van de Walle, B. B. Kaufer, N. Chbab, and N. Osterrieder Analysis of the Herpesvirus Chemokine-binding Glycoprotein G Residues Essential for Chemokine Binding and Biological Activity J. Biol. Chem., February 27, 2009; 284(9): 5968 - 5976. [Abstract] [Full Text] [PDF]

				J. Storlie, W. Jackson, J. Hutchinson, and C. Grose Delayed Biosynthesis of Varicella-Zoster Virus Glycoprotein C: Upregulation by Hexamethylene Bisacetamide and Retinoic Acid Treatment of Infected Cells J. Virol., October 1, 2006; 80(19): 9544 - 9556. [Abstract] [Full Text] [PDF]

				B. K. Tischer, D. Schumacher, D. Chabanne-Vautherot, V. Zelnik, J.-F. Vautherot, and N. Osterrieder High-Level Expression of Marek's Disease Virus Glycoprotein C Is Detrimental to Virus Growth In Vitro J. Virol., May 15, 2005; 79(10): 5889 - 5899. [Abstract] [Full Text] [PDF]

				A. Valsamakis, H. Schneider, P. G. Auwaerter, H. Kaneshima, M. A. Billeter, and D. E. Griffin Recombinant Measles Viruses with Mutations in the C, V, or F Gene Have Altered Growth Phenotypes In Vivo J. Virol., October 1, 1998; 72(10): 7754 - 7761. [Abstract] [Full Text] [PDF]

				J. F. Moffat, L. Zerboni, P. R. Kinchington, C. Grose, H. Kaneshima, and A. M. Arvin Attenuation of the Vaccine Oka Strain of Varicella-Zoster Virus and Role of Glycoprotein C in Alphaherpesvirus Virulence Demonstrated in the SCID-hu Mouse J. Virol., February 1, 1998; 72(2): 965 - 974. [Abstract] [Full Text] [PDF]